Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,651 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
Furuya K, Nakajima M, Tsunedomi R, Nakagami Y, Xu M, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Tomochika S, Maeda N, Iida M, Suzuki N, Takeda S, Hazama S, Ioka T, Hoshii Y, Ueno T, Nagano H. Furuya K, et al. Among authors: xu m. BMC Cancer. 2024 Feb 2;24(1):165. doi: 10.1186/s12885-024-11924-4. BMC Cancer. 2024. PMID: 38308214 Free PMC article.
Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer.
Yamada K, Hazama S, Suzuki N, Xu M, Nakagami Y, Fujiwara N, Tsunedomi R, Yoshida S, Tomochika S, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Watanabe Y, Iida M, Takeda S, Ioka T, Ueno T, Ogihara H, Hamamoto Y, Hoshii Y, Kawano H, Fujita T, Kawakami Y, Nagano H. Yamada K, et al. Among authors: xu m. Oncol Lett. 2021 Jan;21(1):10. doi: 10.3892/ol.2020.12271. Epub 2020 Nov 3. Oncol Lett. 2021. PMID: 33240416 Free PMC article.
Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer.
Chidimatsu H, Tsunedomi R, Nakagami Y, Xu M, Nakajima M, Nakashima-Nakasuga C, Tomochika S, Yoshida S, Suzuki N, Watanabe Y, Matsui H, Shindo Y, Tokumitsu Y, Iida M, Takeda S, Ioka T, Ueno T, Tanabe T, Hoshii Y, Hazama S, Nagano H. Chidimatsu H, et al. Among authors: xu m. Anticancer Res. 2023 Jan;43(1):105-114. doi: 10.21873/anticanres.16139. Anticancer Res. 2023. PMID: 36585204
Serum LOX-1 is a novel prognostic biomarker of colorectal cancer.
Nakashima-Nakasuga C, Hazama S, Suzuki N, Nakagami Y, Xu M, Yoshida S, Tomochika S, Fujiwara N, Matsukuma S, Matsui H, Tokumitsu Y, Kanekiyo S, Shindo Y, Maeda N, Tsunedomi R, Iida M, Takeda S, Yoshino S, Ueno T, Hamamoto Y, Ogihara H, Hoshii Y, Nagano H. Nakashima-Nakasuga C, et al. Among authors: xu m. Int J Clin Oncol. 2020 Jul;25(7):1308-1317. doi: 10.1007/s10147-020-01673-2. Epub 2020 Apr 11. Int J Clin Oncol. 2020. PMID: 32277394
Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial.
Matsui HM, Hazama S, Nakajima M, Xu M, Matsukuma S, Tokumitsu Y, Shindo Y, Tomochika S, Yoshida S, Iida M, Suzuki N, Takeda S, Yoshino S, Ueno T, Oka M, Nagano H. Matsui HM, et al. Among authors: xu m. Cancer Immunol Immunother. 2021 Apr;70(4):945-957. doi: 10.1007/s00262-020-02737-y. Epub 2020 Oct 19. Cancer Immunol Immunother. 2021. PMID: 33074442 Free PMC article. Clinical Trial.
Correction to: Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial.
Matsui H, Hazama S, Nakajima M, Xu M, Matsukuma S, Tokumitsu Y, Shindo Y, Tomochika S, Yoshida S, Iida M, Suzuki N, Takeda S, Yoshino S, Ueno T, Oka M, Nagano H. Matsui H, et al. Among authors: xu m. Cancer Immunol Immunother. 2021 Apr;70(4):959. doi: 10.1007/s00262-020-02819-x. Cancer Immunol Immunother. 2021. PMID: 33399934 Free PMC article. No abstract available.
Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial.
Nakajima M, Hazama S, Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakagami Y, Tamada K, Udaka K, Sakamoto M, Saito A, Kouki Y, Uematsu T, Xu M, Iida M, Tsunedomi R, Suzuki N, Takeda S, Ioka T, Doi S, Nagano H. Nakajima M, et al. Among authors: xu m. Hepatol Res. 2023 Jul;53(7):649-660. doi: 10.1111/hepr.13900. Epub 2023 Mar 30. Hepatol Res. 2023. PMID: 36929310
[No title available]
[No authors listed] [No authors listed] PMID: 37198335
IL-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal Cancer.
Yamamoto T, Tsunedomi R, Nakajima M, Suzuki N, Yoshida S, Tomochika S, Xu M, Nakagami Y, Matsui H, Tokumitsu Y, Shindo Y, Watanabe Y, Iida M, Takeda S, Hazama S, Tanabe T, Ioka T, Hoshii Y, Kiyota A, Takizawa H, Kawakami Y, Ueno T, Nagano H. Yamamoto T, et al. Among authors: xu m. Ann Surg Oncol. 2023 Aug;30(8):5267-5277. doi: 10.1245/s10434-023-13527-y. Epub 2023 May 24. Ann Surg Oncol. 2023. PMID: 37222942
20,651 results
You have reached the last available page of results. Please see the User Guide for more information.